Refractory acute lymphocytic leukemia: Response to aclacinomycin A and VP-16-213

J. M. Rowe, Alex Y Chang, J. M. Bennett

Research output: Contribution to journalArticle

Abstract

Tweleve patients with acute lymphoblastic leukemia (ALL) were treated with aclacinomycin A (60 mg/m2/day for five days) and VP-16-213 (100 mg/m2/day). All were heavily pretreated and had relapsed or were refractory to primary or subsequent treatment. Eight patients were refractory to reinduction therapy given for first, second, third or fourth relapse. One patient was treated in third relapse; one in second relapse (after a short second remission) and two in first relapse - one with the Ph1 chromosome, after a four-month remission, and one patient who relapsed while receiving consolidation therapy. Four patients (33 per cent) responded, three entered complete remission (25 per cent), and one a partial remission (8 per cent). Two of the patients treated for refractoriness to reinduction therapy went into complete remission. Side effects from this treatment were similar to the conventional DAT regimen (daunorubicin, cytosine arabinoside, thioguanine), although the gastrointestinal toxicity and mucositis appeared to be more severe in this study population. One of the patients had severe ventricular arrhythmias which contributed to her death. The complete remission rate (25 per cent) in this group of very heavily pretreated ALL patients warrants further studies to evaluate these preliminary findings.

Original languageEnglish (US)
Pages (from-to)405-410
Number of pages6
JournalHematological Oncology
Volume7
Issue number6
StatePublished - 1989
Externally publishedYes

Fingerprint

Aclarubicin
Etoposide
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Thioguanine
Therapeutics
Philadelphia Chromosome
Mucositis
Daunorubicin
Cytarabine
Cardiac Arrhythmias

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Refractory acute lymphocytic leukemia : Response to aclacinomycin A and VP-16-213. / Rowe, J. M.; Chang, Alex Y; Bennett, J. M.

In: Hematological Oncology, Vol. 7, No. 6, 1989, p. 405-410.

Research output: Contribution to journalArticle

@article{2412a97339ca4940957fda0e026eafdc,
title = "Refractory acute lymphocytic leukemia: Response to aclacinomycin A and VP-16-213",
abstract = "Tweleve patients with acute lymphoblastic leukemia (ALL) were treated with aclacinomycin A (60 mg/m2/day for five days) and VP-16-213 (100 mg/m2/day). All were heavily pretreated and had relapsed or were refractory to primary or subsequent treatment. Eight patients were refractory to reinduction therapy given for first, second, third or fourth relapse. One patient was treated in third relapse; one in second relapse (after a short second remission) and two in first relapse - one with the Ph1 chromosome, after a four-month remission, and one patient who relapsed while receiving consolidation therapy. Four patients (33 per cent) responded, three entered complete remission (25 per cent), and one a partial remission (8 per cent). Two of the patients treated for refractoriness to reinduction therapy went into complete remission. Side effects from this treatment were similar to the conventional DAT regimen (daunorubicin, cytosine arabinoside, thioguanine), although the gastrointestinal toxicity and mucositis appeared to be more severe in this study population. One of the patients had severe ventricular arrhythmias which contributed to her death. The complete remission rate (25 per cent) in this group of very heavily pretreated ALL patients warrants further studies to evaluate these preliminary findings.",
author = "Rowe, {J. M.} and Chang, {Alex Y} and Bennett, {J. M.}",
year = "1989",
language = "English (US)",
volume = "7",
pages = "405--410",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Refractory acute lymphocytic leukemia

T2 - Response to aclacinomycin A and VP-16-213

AU - Rowe, J. M.

AU - Chang, Alex Y

AU - Bennett, J. M.

PY - 1989

Y1 - 1989

N2 - Tweleve patients with acute lymphoblastic leukemia (ALL) were treated with aclacinomycin A (60 mg/m2/day for five days) and VP-16-213 (100 mg/m2/day). All were heavily pretreated and had relapsed or were refractory to primary or subsequent treatment. Eight patients were refractory to reinduction therapy given for first, second, third or fourth relapse. One patient was treated in third relapse; one in second relapse (after a short second remission) and two in first relapse - one with the Ph1 chromosome, after a four-month remission, and one patient who relapsed while receiving consolidation therapy. Four patients (33 per cent) responded, three entered complete remission (25 per cent), and one a partial remission (8 per cent). Two of the patients treated for refractoriness to reinduction therapy went into complete remission. Side effects from this treatment were similar to the conventional DAT regimen (daunorubicin, cytosine arabinoside, thioguanine), although the gastrointestinal toxicity and mucositis appeared to be more severe in this study population. One of the patients had severe ventricular arrhythmias which contributed to her death. The complete remission rate (25 per cent) in this group of very heavily pretreated ALL patients warrants further studies to evaluate these preliminary findings.

AB - Tweleve patients with acute lymphoblastic leukemia (ALL) were treated with aclacinomycin A (60 mg/m2/day for five days) and VP-16-213 (100 mg/m2/day). All were heavily pretreated and had relapsed or were refractory to primary or subsequent treatment. Eight patients were refractory to reinduction therapy given for first, second, third or fourth relapse. One patient was treated in third relapse; one in second relapse (after a short second remission) and two in first relapse - one with the Ph1 chromosome, after a four-month remission, and one patient who relapsed while receiving consolidation therapy. Four patients (33 per cent) responded, three entered complete remission (25 per cent), and one a partial remission (8 per cent). Two of the patients treated for refractoriness to reinduction therapy went into complete remission. Side effects from this treatment were similar to the conventional DAT regimen (daunorubicin, cytosine arabinoside, thioguanine), although the gastrointestinal toxicity and mucositis appeared to be more severe in this study population. One of the patients had severe ventricular arrhythmias which contributed to her death. The complete remission rate (25 per cent) in this group of very heavily pretreated ALL patients warrants further studies to evaluate these preliminary findings.

UR - http://www.scopus.com/inward/record.url?scp=0024463063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024463063&partnerID=8YFLogxK

M3 - Article

C2 - 2807178

AN - SCOPUS:0024463063

VL - 7

SP - 405

EP - 410

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 6

ER -